CN1636229B - 引发单核树突细胞和t细胞th-1应答的组合物和方法 - Google Patents

引发单核树突细胞和t细胞th-1应答的组合物和方法 Download PDF

Info

Publication number
CN1636229B
CN1636229B CN028198174A CN02819817A CN1636229B CN 1636229 B CN1636229 B CN 1636229B CN 028198174 A CN028198174 A CN 028198174A CN 02819817 A CN02819817 A CN 02819817A CN 1636229 B CN1636229 B CN 1636229B
Authority
CN
China
Prior art keywords
cell
interleukin
cells
dendritic cells
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN028198174A
Other languages
English (en)
Chinese (zh)
Other versions
CN1636229A (zh
Inventor
M·L·博施
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Northwest Biotherapeutics LLC
Original Assignee
Northwest Biotherapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northwest Biotherapeutics LLC filed Critical Northwest Biotherapeutics LLC
Priority to CN201210470111.XA priority Critical patent/CN102973928B/zh
Publication of CN1636229A publication Critical patent/CN1636229A/zh
Application granted granted Critical
Publication of CN1636229B publication Critical patent/CN1636229B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/72—Undefined extracts from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
CN028198174A 2001-09-06 2002-09-06 引发单核树突细胞和t细胞th-1应答的组合物和方法 Expired - Fee Related CN1636229B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201210470111.XA CN102973928B (zh) 2001-09-06 2002-09-06 引发单核树突细胞和t细胞th-1应答的组合物和方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31759201P 2001-09-06 2001-09-06
US60/317,592 2001-09-06
PCT/US2002/028620 WO2003022215A2 (en) 2001-09-06 2002-09-06 Compositions and methods for priming monocytic dendritic cells and t cells for th-1 response

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201210470111.XA Division CN102973928B (zh) 2001-09-06 2002-09-06 引发单核树突细胞和t细胞th-1应答的组合物和方法

Publications (2)

Publication Number Publication Date
CN1636229A CN1636229A (zh) 2005-07-06
CN1636229B true CN1636229B (zh) 2012-12-19

Family

ID=32654226

Family Applications (2)

Application Number Title Priority Date Filing Date
CN028198174A Expired - Fee Related CN1636229B (zh) 2001-09-06 2002-09-06 引发单核树突细胞和t细胞th-1应答的组合物和方法
CN201210470111.XA Expired - Fee Related CN102973928B (zh) 2001-09-06 2002-09-06 引发单核树突细胞和t细胞th-1应答的组合物和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201210470111.XA Expired - Fee Related CN102973928B (zh) 2001-09-06 2002-09-06 引发单核树突细胞和t细胞th-1应答的组合物和方法

Country Status (17)

Country Link
US (2) US20050059151A1 (enExample)
EP (3) EP3653055A1 (enExample)
JP (3) JP2005505270A (enExample)
KR (3) KR101803702B1 (enExample)
CN (2) CN1636229B (enExample)
AU (1) AU2008221592B2 (enExample)
BR (1) BRPI0212545B8 (enExample)
CA (1) CA2459713C (enExample)
DK (2) DK2322603T3 (enExample)
ES (2) ES2598109T3 (enExample)
IL (3) IL160720A0 (enExample)
MX (1) MXPA04002147A (enExample)
NO (2) NO338147B1 (enExample)
NZ (1) NZ531530A (enExample)
PL (1) PL372098A1 (enExample)
PT (2) PT2322603T (enExample)
WO (1) WO2003022215A2 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT412145B (de) * 2002-09-13 2004-10-25 Forsch Krebskranke Kinder Verfahren zur herstellung eines zellulären immuntherapeutikums auf basis von il-12-freisetzenden dendritischen zellen
US20040057935A1 (en) * 2002-09-20 2004-03-25 Cedars-Sinai Medical Center Intratumoral delivery of dendritic cells
CN102600461B (zh) * 2002-12-06 2017-07-14 西北生物治疗药物公司 给予体外部分成熟的树突细胞治疗肿瘤
RU2364625C2 (ru) * 2003-02-27 2009-08-20 Норсуэст Байотерапьютикс, Инк. Генерирование дендритных клеток из моноцитарных предшественников дендритных клеток с помощью gm-csf в отсутствие дополнительных цитокинов
EP1484064A1 (en) 2003-06-04 2004-12-08 Gesellschaft für Biotechnologische Forschung Therapeutical composition containing dentritic cells and use thereof
EP1670513B1 (en) * 2003-10-06 2013-01-23 Cedars-Sinai Medical Center Cox-2 inhibitors and dendritic cells for use in the treatment of cancer.
JP5015601B2 (ja) * 2003-10-21 2012-08-29 セダーズ−シナイ メディカル センター 中枢神経系の癌を含む癌の処置のための系および方法
WO2005042737A1 (ja) * 2003-11-04 2005-05-12 Dnavec Research Inc. 遺伝子導入された樹状細胞の製造方法
WO2006001120A1 (ja) 2004-06-24 2006-01-05 Dnavec Research Inc. マイナス鎖rnaウイルスを含む抗癌剤
KR20220113543A (ko) * 2005-12-08 2022-08-12 노쓰웨스트 바이오써라퓨틱스, 인크. 미성숙 단핵구성 수지상 세포의 활성화를 유도하기 위한 조성물 및 방법
EP1840206A1 (en) * 2006-03-28 2007-10-03 Gsf-Forschungszentrum Für Umwelt Und Gesundheit, Gmbh Compositions for the preparation of mature dendritic cells
CA2700573C (en) 2006-09-26 2016-11-22 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
CA2700436C (en) 2006-09-28 2017-04-18 John S. Yu Cancer vaccines and vaccination methods
PL2328923T3 (pl) 2008-09-02 2016-06-30 Cedars Sinai Medical Center Epitopy CD133
EP2427485B1 (en) * 2009-05-07 2016-12-07 ImmunoCellular Therapeutics, Ltd. Cd133 epitopes
NZ628292A (en) * 2012-02-02 2016-09-30 Neostem Oncology Llc Pluripotent germ layer origin antigen presenting cancer vaccine
KR101704745B1 (ko) * 2012-05-31 2017-02-08 제이더블유크레아젠 주식회사 수지상세포 성숙화 조성물 및 이를 이용하여 항원 특이적 수지상세포를 제조하는 방법
AU2020203845C1 (en) * 2012-09-06 2022-08-11 Orbis Health Solutions, Llc Tumor lysate loaded particles
US9744193B2 (en) 2012-09-06 2017-08-29 Orbis Health Solutions Llc Tumor lysate loaded particles
CN104981258B (zh) 2012-12-12 2017-10-20 奥比思健康解决方案有限责任公司 用于组织再生的组合物、其制备方法及其用途
ES2662333T3 (es) 2013-02-14 2018-04-06 Immunocellular Therapeutics Ltd. Vacunas contra el cáncer y métodos de vacunación
CN104936612B (zh) * 2013-09-05 2021-01-01 奥比思健康解决方案有限责任公司 装载了肿瘤裂解物的微粒
US10166195B2 (en) 2014-03-05 2019-01-01 Orbis Health Solutions, Llc Vaccine delivery systems using yeast cell wall particles
US11669090B2 (en) 2014-05-20 2023-06-06 State Farm Mutual Automobile Insurance Company Autonomous vehicle operation feature monitoring and evaluation of effectiveness
US9972054B1 (en) 2014-05-20 2018-05-15 State Farm Mutual Automobile Insurance Company Accident fault determination for autonomous vehicles
US10599155B1 (en) 2014-05-20 2020-03-24 State Farm Mutual Automobile Insurance Company Autonomous vehicle operation feature monitoring and evaluation of effectiveness
US10373259B1 (en) 2014-05-20 2019-08-06 State Farm Mutual Automobile Insurance Company Fully autonomous vehicle insurance pricing
US10354330B1 (en) 2014-05-20 2019-07-16 State Farm Mutual Automobile Insurance Company Autonomous feature use monitoring and insurance pricing
US9786154B1 (en) 2014-07-21 2017-10-10 State Farm Mutual Automobile Insurance Company Methods of facilitating emergency assistance
US10241509B1 (en) 2014-11-13 2019-03-26 State Farm Mutual Automobile Insurance Company Autonomous vehicle control assessment and selection
EP3317402B1 (en) 2015-06-30 2024-02-14 Universidade Nova de Lisboa A viable cell population, method for production and uses thereof
IL256522B2 (en) * 2015-06-30 2024-10-01 Northwest Biotherapeutics Inc Optimally activated dendritic cells that result in an enhanced or enhanced antitumor immune response
US11107365B1 (en) 2015-08-28 2021-08-31 State Farm Mutual Automobile Insurance Company Vehicular driver evaluation
US11719545B2 (en) 2016-01-22 2023-08-08 Hyundai Motor Company Autonomous vehicle component damage and salvage assessment
US10324463B1 (en) 2016-01-22 2019-06-18 State Farm Mutual Automobile Insurance Company Autonomous vehicle operation adjustment based upon route
US10134278B1 (en) 2016-01-22 2018-11-20 State Farm Mutual Automobile Insurance Company Autonomous vehicle application
US10395332B1 (en) 2016-01-22 2019-08-27 State Farm Mutual Automobile Insurance Company Coordinated autonomous vehicle automatic area scanning
US10503168B1 (en) 2016-01-22 2019-12-10 State Farm Mutual Automotive Insurance Company Autonomous vehicle retrieval
US11242051B1 (en) 2016-01-22 2022-02-08 State Farm Mutual Automobile Insurance Company Autonomous vehicle action communications
US11441916B1 (en) 2016-01-22 2022-09-13 State Farm Mutual Automobile Insurance Company Autonomous vehicle trip routing
KR102038114B1 (ko) * 2016-02-26 2019-10-30 주식회사 엘지화학 광학 점착제용 (메타)아크릴레이트기 함유 벤조페논의 제조방법 및 광학 점착제 조성물
US12059434B2 (en) 2017-02-28 2024-08-13 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Short-term activated DC1s and methods for their production and use
WO2019183924A1 (en) * 2018-03-30 2019-10-03 Syz Cell Therapy Co. Improved multiple antigen specific cell therapy methods
JP2022552200A (ja) * 2019-10-07 2022-12-15 ノースウエスト バイオセラピューティクス，インコーポレイティド 樹状細胞およびＴ細胞の活性化を増強するためのならびにＴＨ－１免疫応答を誘導するためのｉｎ ｖｉｔｒｏの方法および組成物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1229359A (zh) * 1995-10-04 1999-09-22 依默耐克斯有限公司 树突状细胞刺激因子
CN1304448A (zh) * 1999-04-01 2001-07-18 科学技术振兴事业团 人树突状细胞表达基因群
US6274378B1 (en) * 1997-10-27 2001-08-14 The Rockefeller University Methods and compositions for obtaining mature dendritic cells

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5162504A (en) 1988-06-03 1992-11-10 Cytogen Corporation Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
US5366866A (en) * 1991-07-25 1994-11-22 Duke University Method of diagnosing ovarian and endometrial cancer with monoclonal antibodies OXA and OXB
US5227471A (en) * 1992-01-30 1993-07-13 Eastern Virginia Medical School Of The Medical College Of Hampton Roads Monoclonal antibody PD41 that binds to a prostate mucin antigen that is expressed in human prostatic carcinoma
US5788963A (en) 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
US7659119B2 (en) * 1996-02-12 2010-02-09 Argos Therapeutics, Inc. Method and compositions for obtaining mature dendritic cells
JP2000143534A (ja) * 1998-11-13 2000-05-23 Asahi Chem Ind Co Ltd 樹状細胞ワクチン及びその製造方法
AU2403901A (en) * 1999-12-28 2001-07-09 Ichiro Azuma Maturation-promoting agent for immature dendritic cells
US6247378B1 (en) * 2000-01-06 2001-06-19 Deere & Company Operator control device for an infinitely variable transmission
US20030175247A1 (en) * 2000-05-12 2003-09-18 Michael Salgaller Method to increase class I presentation of exogenous antigens by human dendritic cells
DE60117167T2 (de) * 2001-01-15 2006-10-05 I.D.M. Immuno-Designed Molecules Verfahren zur herstellung von submikropartikel-suspensionen pharmazeutischer substanzen
AU2002326463A1 (en) * 2001-07-25 2003-02-17 Northwest Biotherapeutics, Inc. Methods and apparatus for enrichment and culture of monocytic dendritic cell precursors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1229359A (zh) * 1995-10-04 1999-09-22 依默耐克斯有限公司 树突状细胞刺激因子
US6274378B1 (en) * 1997-10-27 2001-08-14 The Rockefeller University Methods and compositions for obtaining mature dendritic cells
CN1304448A (zh) * 1999-04-01 2001-07-18 科学技术振兴事业团 人树突状细胞表达基因群

Also Published As

Publication number Publication date
MXPA04002147A (es) 2005-03-07
CA2459713A1 (en) 2003-03-20
EP3653055A1 (en) 2020-05-20
JP6114768B2 (ja) 2017-04-12
HK1079989A1 (en) 2006-04-21
EP2322603B1 (en) 2019-10-16
AU2008221592A1 (en) 2008-10-16
JP2015107133A (ja) 2015-06-11
IL219266A (en) 2014-02-27
EP1441591A2 (en) 2004-08-04
KR101803702B1 (ko) 2017-12-01
US20050059151A1 (en) 2005-03-17
AU2008221592B2 (en) 2012-12-20
WO2003022215A3 (en) 2003-11-13
ES2766299T3 (es) 2020-06-12
ES2598109T3 (es) 2017-01-25
IL160720A (en) 2012-05-31
KR20050027163A (ko) 2005-03-17
CN1636229A (zh) 2005-07-06
EP1441591B1 (en) 2016-06-29
CA2459713C (en) 2015-08-18
BR0212545A (pt) 2005-01-18
BRPI0212545B1 (pt) 2019-12-03
WO2003022215A2 (en) 2003-03-20
JP2005505270A (ja) 2005-02-24
DK2322603T3 (da) 2020-01-27
IL160720A0 (en) 2004-08-31
CN102973928B (zh) 2019-03-15
PT2322603T (pt) 2020-01-21
JP5777956B2 (ja) 2015-09-16
IL219266A0 (en) 2012-06-28
EP2322603A1 (en) 2011-05-18
BRPI0212545A8 (pt) 2019-10-15
NO20040965L (no) 2004-04-23
PL372098A1 (en) 2005-07-11
NO338147B1 (no) 2016-08-01
PT1441591T (pt) 2016-10-06
DK1441591T3 (en) 2017-05-22
JP2011188872A (ja) 2011-09-29
EP1441591A4 (en) 2006-06-07
CN102973928A (zh) 2013-03-20
NZ531530A (en) 2007-01-26
BRPI0212545B8 (pt) 2021-05-25
NO20151562A1 (no) 2015-11-16
KR20110081341A (ko) 2011-07-13
KR20140116544A (ko) 2014-10-02
US20080254064A1 (en) 2008-10-16

Similar Documents

Publication Publication Date Title
CN1636229B (zh) 引发单核树突细胞和t细胞th-1应答的组合物和方法
US20120244620A1 (en) Compositions and methods for inducing the activation of immature monocytic dendritic cells
CN115461073A (zh) 用于增强树突细胞和T细胞激活以及用于诱导Th-1免疫应答的体外方法和组合物
AU2013201707B2 (en) Compositions and methods for priming monocytic dendritic cells and T cells for Th-1 response
HK1079989B (en) Compositions and methods for priming monocytic dendritic cells and t cells for th-1 response
HK1157819A (en) Compositions and methods for priming monocytic dendritic cells and t cells for th1 response
AU2002326846A1 (en) Compositions and methods for priming monocytic dendritic cells and T cells for Th-1 response
HK1157819B (en) Compositions and methods for priming monocytic dendritic cells and t cells for th1 response
AU2013206016B2 (en) Compositions and methods for inducing the activation of immature monocytic dendritic cells
HK40085184A (en) In vitro methods and compositions for enhancing the activation of dendritic cells and t cells, and for inducing a th-1 immune response
HK40051623A (en) Compositions and methods for inducing the activation of immature monocytic dendritic cells

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1079989

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1079989

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20121219

Termination date: 20210906